Core Insights - The article discusses the 12 best healthcare stocks to buy and hold for five years, highlighting the role of AI in improving healthcare services and addressing insurance denials [1][4]. Group 1: AI in Healthcare - Dr. Warris Bokhari's platform utilizes AI to appeal health insurance denials for approximately 70 autoimmune diseases, addressing a significant issue where 850 million denials occur annually in the U.S. [2][3]. - The platform was launched on October 2, 2024, and aims to assist patients in navigating care denials by generating appeal letters based on healthcare plans [4]. Group 2: Stock Selection Methodology - The selection of the top healthcare stocks was based on criteria including EPS growth of over 10% in the past five years, an expected EPS growth rate of at least 20% over the next five years, and a forward PE ratio greater than 20 [6]. - The final ranking of stocks was influenced by the number of hedge fund holders as tracked by the Insider Monkey database as of Q2 2025 [6][7]. Group 3: Company Highlights - **Intuitive Surgical, Inc. (NASDAQ:ISRG)**: Pioneered robotic-assisted minimally invasive surgery with its da Vinci systems, which are used globally. The company introduced advanced software features for its da Vinci 5 system in September 2025, enhancing surgical capabilities [9][10]. - **Doximity, Inc. (NYSE:DOCS)**: A leading healthcare technology stock that completed the acquisition of Pathway Medical, enhancing its AI-driven tools. The company reported a 15% year-over-year revenue increase, reaching $145.9 million for the quarter ending June 30, 2025 [13][15]. - **Penumbra, Inc. (NYSE:PEN)**: A leader in thrombectomy and vascular intervention technologies, recently introduced the Ruby XL System and the Lightning Bolt 6X device, expanding its product offerings and market reach [16][18].

Core Insights - Virtual healthcare and physician-focused digital platforms are transforming U.S. healthcare delivery, with Hims & Hers Health, Inc. and Doximity, Inc. leading the charge [1][2] - Hims & Hers focuses on consumer access and affordability, while Doximity leverages its physician network and enterprise solutions [2] Stock Performance & Valuation - Hims & Hers has increased by 208.8% over the past year, outperforming Doximity's 73.4% gain, although Doximity has outperformed Hims & Hers in the last three months with a 21.8% increase compared to Hims' 11.1% [3][6] - Hims & Hers has a forward price-to-sales (P/S) ratio of 4.6, while Doximity's is at 20.9, both above their respective three-year medians [5] - Hims & Hers has a Zacks Style Score with a Growth Score of A, while Doximity has a Growth Score of B [5] Growth Drivers for Hims & Hers - Hims & Hers is diversifying its offerings into areas like weight loss and chronic conditions, with the rollout of generic semaglutide presenting a significant opportunity [7] - The company is expanding internationally, with plans to enter Canada in 2026 and the acquisition of ZAVA enhancing its European presence [7] - Hims & Hers is investing in AI to improve diagnostics and treatment personalization, aiming for a technology-driven healthcare platform [8] Growth Drivers for Doximity - Doximity has over 80% of U.S. physicians active on its platform, with high engagement levels and a sticky ecosystem that supports recurring revenue growth [10] - The launch of Doximity Scribe, which automates clinical note-taking, has seen strong adoption, with over 75% of users returning weekly [11] - Doximity's growth is supported by strong adoption among pharmaceutical and health system clients, contributing to broad-based revenue growth [12] Earnings Projections - The Zacks Consensus Estimate for Hims & Hers suggests a 122.2% improvement in earnings per share (EPS) from 2024 to 2025 [15] - Doximity's fiscal 2026 EPS is projected to improve by 6.3% from fiscal 2025 [17] Price Targets - The average price target for Hims & Hers is $48.67, indicating a potential decline of 11.3% from the last close [20] - The average price target for Doximity is $68.83, suggesting a potential increase of 7.5% from the last close [23] Investment Considerations - Hims & Hers is viewed as a more stable investment opportunity with strong profitability and user engagement, while Doximity is rapidly expanding but may be trading at a higher valuation [24][25] - Both companies are ranked 3 (Hold) by Zacks, but Hims & Hers is considered to have a more capital-efficient model and better growth prospects [24][25]

Core Insights - The investment approach focuses on identifying businesses with potential for long-term growth and significant terminal value generation [1] - Emphasis is placed on understanding core business economics, including competitive advantages, unit economics, reinvestment opportunities, and management quality [1] - The goal is to generate long-term free cash flow and create shareholder value through fundamental research in sectors with strong secular tailwinds [1] Investment Philosophy - The investor is self-educated with a decade of experience in managing personal funds, primarily sourced from friends and family [1] - The motivation for sharing insights is to provide value to readers and receive feedback from the investment community [1] - The analysis aims to highlight the key drivers of long-term equity value, ensuring that it is both analytical and accessible [1]

Company Performance - Doximity (DOCS) closed at $73.60, with a daily increase of +1.28%, outperforming the S&P 500's gain of 0.48% [1] - The stock has risen by 12.91% over the past month, leading the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46% [1] Upcoming Earnings - Doximity is expected to report EPS of $0.38, reflecting a 26.67% increase from the prior-year quarter [2] - The projected revenue for the upcoming earnings is $157.73 million, up 15.27% from the year-ago period [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $1.5 per share, indicating a +5.63% change from the previous year [3] - Revenue for the fiscal year is projected at $632.56 million, showing a +10.9% increase from the prior year [3] Analyst Estimates - Investors should monitor changes in analyst estimates for Doximity, as positive revisions indicate confidence in business performance [4] - Estimate revisions are correlated with near-term share price momentum, which can be leveraged for investment strategies [5] Zacks Rank and Valuation - Doximity currently holds a Zacks Rank of 3 (Hold), with no changes in the EPS estimate over the past month [6] - The company has a Forward P/E ratio of 48.38, which is higher than the industry average of 38.89 [7] - Doximity's PEG ratio stands at 3.52, compared to the industry average PEG ratio of 3.28 [7] Industry Overview - The Medical Info Systems industry, part of the Medical sector, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [8] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating a favorable environment for investment [8]

Group 1 - Canaccord Genuity raised its price target on Doximity Inc. to $67 from $59 while maintaining a Hold rating [1] - The rapid pace of change in the large language model environment is reshaping healthcare technology, with trust among users being critical for long-term success [1] - Doximity's position in the early stages of the AI transition could allow it to become one of the winners in the space [2] Group 2 - Despite the raised price target, Canaccord maintained its Hold stance due to current valuation levels [2]

Financial Data and Key Metrics Changes - The preliminary results indicate that both Jeff Tangney and Kara Wampler have been elected to serve as directors until the 2028 Annual Meeting [9] - Deloitte's appointment as the independent auditor for fiscal year 2026 has been ratified [9] - The nonbinding advisory vote on named executive officers' compensation has been approved [9] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the provided content Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the provided content Company Strategy and Development Direction and Industry Competition - The company has proposed to elect two class one directors and ratify the independent auditor, indicating a focus on governance and compliance [7][8] - The approval of executive compensation suggests a strategy to align management incentives with shareholder interests [8] Management's Comments on Operating Environment and Future Outlook - No specific comments from management regarding the operating environment or future outlook were provided in the content Other Important Information - The meeting was conducted virtually, and the voting process was outlined to ensure transparency and efficiency [4][5][6] Q&A Session All Questions and Answers - No Q&A session content was provided in the documents

Financial Data and Key Metrics Changes - The preliminary results of the annual meeting indicate that both Jeff Tangney and Kara Wampler have been elected as directors until the 2028 Annual Meeting [8] - Deloitte's appointment as the independent auditor for fiscal year 2026 has been ratified [8] - The nonbinding advisory vote on the compensation of named executive officers for the fiscal year ended March 31, 2025, has been approved [8] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided in the meeting [9] Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting [9] Company Strategy and Development Direction and Industry Competition - The company has proposed to elect two class one directors and ratify the independent auditor, indicating a focus on governance and oversight [6] - The approval of executive compensation suggests a strategy to align management incentives with shareholder interests [7] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting [9] Other Important Information - The meeting was conducted virtually, and voting was completed in accordance with Doximity's Bylaws and Delaware law [2][3] - The meeting was attended by the CEO, CFO, Board of Directors, and representatives from Deloitte, indicating a strong governance structure [2] Q&A Session All Questions and Answers - No Q&A session was recorded or reported in the meeting [9]

Financial Data and Key Metrics Changes - The preliminary results of the annual meeting indicate that both Jeff Tangney and Kara Wampler have been elected as directors until the 2028 Annual Meeting [8] - Deloitte's appointment as the independent auditor for fiscal year 2026 has been ratified [8] - The nonbinding advisory vote on named executive officers' compensation for the fiscal year ended March 31, 2025, has been approved [8] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were discussed in the meeting [9] Market Data and Key Metrics Changes - No specific market data or metrics were provided during the meeting [9] Company Strategy and Development Direction and Industry Competition - The company has recommended the passage of all proposals presented at the meeting, indicating a unified strategy among the Board of Directors [7] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting [9] Other Important Information - The meeting was conducted virtually, and voting was completed in accordance with Doximity's Bylaws and Delaware law [2][3] - The meeting was attended by the CEO, CFO, Board of Directors, and representatives from Deloitte, indicating a strong governance structure [2] Q&A Session All Questions and Answers - No Q&A session was recorded or reported in the meeting [9]

Core Insights - Doximity, Inc. (DOCS) reported adjusted earnings per share (EPS) of 36 cents for Q1 fiscal 2026, marking a 28.6% increase year over year and exceeding the Zacks Consensus Estimate by 16.1% [1][9] - The company's revenues reached $145.9 million in the same quarter, reflecting a 15.2% year-over-year growth and surpassing the Zacks Consensus Estimate by 4.5% [2][9] Revenue Breakdown - Doximity's revenue sources include Subscription and Other, with Subscription revenues totaling $137.9 million, up 14.9% year over year, driven by new and expanding existing customers [3][4] - Other revenues amounted to $8 million, representing a 19.8% increase year over year [4] Margin Analysis - Gross profit for the quarter increased by 15% year over year to $130.1 million, although gross margin contracted by 13 basis points to 89.2% [5] - Operating profit was reported at $54.5 million, an 18.4% increase from the prior year, with the operating margin expanding by 101 basis points to 37.4% [6] Financial Position - At the end of Q1 fiscal 2026, Doximity had cash and cash equivalents of $137.3 million, down from $209.6 million at the end of fiscal 2025 [7] - Net cash provided by operating activities was $62.1 million, compared to $41.2 million a year ago [7] Guidance and Outlook - Doximity raised its full-year revenue outlook to between $628 million and $636 million, up from the previous range of $619 million to $631 million [9][10] - For Q2 fiscal 2026, the company expects revenues between $157 million and $158 million, exceeding the Zacks Consensus Estimate of $150.4 million [10] Performance Highlights - The company reported double-digit growth in unique active users across various metrics, and a record number of unique active prescribers utilized Doximity's workflow tools [12] - The recent launch of Doximity AI scribe is seen as a promising development for the company's future [12]

Core Insights - Doximity Inc reported better-than-expected earnings for Q1, with earnings of 36 cents per share, surpassing the analyst consensus estimate of 30 cents per share [1] - The company achieved quarterly sales of $145.913 million, exceeding the analyst consensus estimate of $139.705 million [1] - Doximity raised its FY2026 sales guidance from a range of $619 million-$631 million to $628 million-$636 million [1] Company Performance - The CEO of Doximity highlighted strong profit growth and record engagement across their newsfeed, workflow, and AI products, with the AI suite growing 5x year-over-year [2] - Over 630,000 prescribers utilized Doximity's workflow tools to enhance efficiency and patient service [2] - Following the earnings announcement, Doximity shares increased by 10.3%, trading at $64.55 [2] Analyst Ratings - Needham analyst Ryan MacDonald maintained a Buy rating on Doximity and raised the price target from $67 to $75 [7] - Wells Fargo analyst Stan Berenshteyn maintained an Equal-Weight rating and increased the price target from $62 to $65 [7]